Medical Licensing (MD/DO) · Independent exam preparation
Reproductive Endocrinology and Infertility Qualifying Examination Study Guide
Practise endocrine interpretation, infertility treatment selection, early-pregnancy assessment, reproductive surgery decisions, and genetic counseling for ABOG REI.
By CertMedbry · Updated 15 October 2026
Interpret discordant hormone results, distinguish causes of amenorrhea, select fertility treatments, prevent ART complications, and explain reproductive genetic risk. These 60 concepts support preparation for the United States ABOG Reproductive Endocrinology and Infertility written Qualifying Examination. They provide selective coverage across all six competency domains; the official issuer-linked outline defines the full scope, including additional procedures, endocrine conditions, and counseling responsibilities.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide address?
The United States American Board of Obstetrics and Gynecology Reproductive Endocrinology and Infertility written Qualifying Examination. The subsequent oral Certifying Examination is a separate stage. The American Osteopathic Board of Obstetrics and Gynecology also offers subspecialty certification, but its requirements are outside this guide's selected pathway.
How many questions are administered, and how many are scored or pretest?
For the 2026 administration, ABOG's Subspecialty Qualifying Examination bulletin states a total of 230 single-best-answer multiple-choice questions. The scored-versus-pretest breakdown remains unverified. The 20 questions here are independent learning exercises and do not represent the examination's length. Source: 2026 ABOG Subspecialty Qualifying Examination bulletin, https://www.abog.org/docs/default-source/bulletins/2026/subspecialty/2026-subspecialties-qe-bulletin.pdf?sfvrsn=28ce2a18_2.
What are the examination duration, delivery method, and adaptivity?
The 2026 ABOG Subspecialty Qualifying Examination bulletin specifies Pearson VUE test-center delivery. Its administration section reports approximately 3 hours 45 minutes, but that sentence inconsistently refers to the 'Specialty' examination within the subspecialty bulletin; this wording prevents treating the duration as unqualified confirmation for REI. Adaptive status and remote-delivery availability remain unverified. Source: 2026 ABOG Subspecialty Qualifying Examination bulletin, https://www.abog.org/docs/default-source/bulletins/2026/subspecialty/2026-subspecialties-qe-bulletin.pdf?sfvrsn=28ce2a18_2.
Which item styles do these exercises represent?
The 2026 ABOG Subspecialty Qualifying Examination bulletin identifies the official format as single-best-answer multiple-choice questions. These exercises use that general format with four options; the official number of options is unverified. These drills are not an oral examination simulation or a prediction of certification performance. Source: 2026 ABOG Subspecialty Qualifying Examination bulletin, https://www.abog.org/docs/default-source/bulletins/2026/subspecialty/2026-subspecialties-qe-bulletin.pdf?sfvrsn=28ce2a18_2.
Which blueprint applies, and does it publish domain weights?
The issuer-linked REI competency PDF documented on October 14, 2026 contains six primary categories. It states no explicit effective or update date and no numeric domain weights; the 2026 URL directory does not establish an effective date. This guide allocates concepts across the domains for breadth, with additional space for endocrine disease and infertility. Its allocation is educational, not an official weighting.
ABOG subspecialty-certification exam blueprint listing · ABOG Reproductive Endocrinology and Infertility competency blueprint
Why does the guide use PMOS alongside PCOS?
The guideline developer documents the May 12, 2026 terminology change from polycystic ovary syndrome, or PCOS, to polyendocrine metabolic ovarian syndrome, or PMOS. Both terms appear here to connect current terminology with familiar clinical literature. This terminology change does not rename the ABOG examination.
Monash PCOS Guideline / PMOS Guideline · Recommendations from the 2023 international evidence-based PMOS guideline
This is physician subspecialty board-certification preparation. ABOG's written Qualifying Examination and subsequent oral Certifying Examination are separate stages. The guide, questions, and flashcards are independent educational materials.
Outline used: Current issuer-linked REI competency blueprint preserved in trusted frozen evidence retrieved on 2026-10-08. Its URL contains a 2026 resource directory, but the readable document states no explicit effective/update date or numeric domain weights. The assigned workbook label denotes ABOG REI subspecialty certification; this preview maps specifically to its written Qualifying Examination, distinct from the subsequent oral Certifying Examination. Live searches on 2026-10-09 identified no evidenced replacement blueprint; fresh issuer retrieval was unsuccessful.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Foundational Reproductive Endocrinologynot stated
1.How do steroid and peptide hormones produce different cellular responses?
Steroid hormones usually cross cell membranes and bind intracellular receptors that regulate transcription. Peptide hormones generally bind surface receptors and activate intracellular signaling pathways. Receptor distribution, downstream signaling, and exposure duration determine the tissue response; serum concentration alone does not describe biological activity. This distinction helps explain why gonadotropins stimulate ovarian steroid production while estradiol and progesterone subsequently change endometrial gene expression and differentiation.
Apply it
A learner compares FSH stimulation of granulosa cells with progesterone exposure of the endometrium. Identify a surface-receptor signaling response for FSH and an intracellular receptor-mediated transcriptional response for progesterone, then connect each to its target tissue.
Common pitfall: A hormone's reproductive role does not identify its receptor class. Avoid assigning the intracellular steroid-receptor mechanism to peptide gonadotropins simply because they influence steroid production.
The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025) · Diagnosis and treatment of luteal phase deficiency (2026)
2.Why do GnRH agonists and antagonists suppress gonadotropins differently?
A GnRH antagonist directly blocks pituitary GnRH receptors, producing rapid suppression without an initial flare. Continuous GnRH agonist exposure initially stimulates secretion, then produces receptor desensitization and suppression. Conversely, an agonist trigger during an antagonist stimulation cycle can exploit a responsive pituitary to generate an endogenous gonadotropin surge. The treatment sequence therefore matters: the same agonist cannot be interpreted independently of prior pituitary suppression and the intended treatment purpose.
Apply it
An IVF patient has received a GnRH antagonist and develops a very high follicle count. Explain why an agonist can now serve as a maturation trigger, even though prolonged agonist administration is also used to suppress gonadotropins.
Common pitfall: Do not equate every GnRH agonist exposure with immediate suppression. Initial stimulation, subsequent desensitization, and trigger use are different pharmacodynamic situations with different clinical consequences.
Prevention of moderate and severe ovarian hyperstimulation syndrome (2023)
3.Why does hCG exposure matter when selecting an oocyte-maturation trigger?
LH and hCG activate the same receptor, allowing hCG to support final oocyte maturation and luteal steroid production. However, hCG provides more sustained receptor stimulation than the endogenous surge induced by a GnRH agonist. In a strongly responding ovary, this prolonged luteotropic signal contributes to ovarian hyperstimulation syndrome through increased vascular permeability. Trigger selection therefore depends on both maturation efficacy and the patient's anticipated response-related complication risk.
Apply it
Two patients have different ovarian responses to otherwise similar stimulation. For the patient with many developing follicles, connect prolonged hCG action to increased OHSS concern and explain why a shorter endogenous surge may improve the safety strategy.
Common pitfall: Equivalent receptor targets do not make LH and hCG pharmacologically interchangeable. Duration of stimulation changes the clinical consequences, particularly when many follicles have developed.
Prevention of moderate and severe ovarian hyperstimulation syndrome (2023)
4.How does estrogen administration route change systemic exposure?
Oral estrogen passes through the liver before reaching the systemic circulation, whereas transdermal estradiol avoids this initial hepatic passage. Route therefore changes hepatic exposure and cannot be reduced to a simple comparison of tablet and patch amounts. For primary ovarian insufficiency, hormone replacement is selected to address estrogen deficiency and individual risks. If the uterus is present, systemic estrogen generally requires adequate progestogen protection of the endometrium.
Apply it
A patient with ovarian insufficiency asks whether an oral tablet and an estradiol patch are identical treatments. Explain their different routes of exposure and establish whether she has a uterus before discussing the accompanying progestogen requirement.
Common pitfall: Do not compare formulations solely by their printed amounts or assume transdermal delivery eliminates the need for endometrial protection when systemic estrogen reaches an intact uterus.
Evidence-based guideline: Premature Ovarian Insufficiency (2025)
5.Why must basal FSH be interpreted with estradiol?
Early follicular FSH reflects pituitary stimulation under ovarian feedback, but an elevated early estradiol concentration can suppress FSH into an apparently reassuring range. Consequently, a normal FSH does not exclude diminished ovarian reserve when estradiol is already elevated. Basal FSH also varies between cycles and is relatively insensitive. Interpret cycle timing, estradiol, age, and other reserve markers together rather than treating one normal gonadotropin result as proof of normal reserve.
Apply it
A 39-year-old has a normal early follicular FSH but unexpectedly elevated estradiol. Explain that estradiol may be masking an FSH rise, and integrate age, antral follicle count, and AMH when counseling about likely stimulation response.
Common pitfall: A laboratory result inside its reference interval is not automatically reassuring. Feedback effects and collection timing can make an apparently normal FSH clinically misleading.
6.What does AMH measure about ovarian reserve?
AMH is produced by granulosa cells of small growing follicles and is useful for estimating the recruitable follicular pool and anticipated response to stimulation. It is not a direct measure of oocyte chromosomal competence or a reliable standalone prediction of spontaneous conception. Age remains central to reproductive prognosis. AMH and antral follicle count are especially useful when planning stimulation, but unusually low results should inform counseling rather than automatically exclude treatment.
Apply it
A regularly cycling 30-year-old interprets a low AMH as proof she cannot conceive naturally. Explain the distinction between expected oocyte yield during stimulation and the probability of conception, then assess her actual reproductive history and goals.
Common pitfall: Do not translate a low AMH into sterility or a high AMH into excellent egg quality. Reserve quantity and reproductive competence answer different questions.
7.When should the prolactin hook effect be suspected, and how is it distinguished from stalk-related elevation?
Suspect the high-dose hook effect when a very large pituitary mass accompanies an unexpectedly modest prolactin concentration. In a susceptible two-site immunoassay, extreme antigen excess saturates capture and detection antibodies separately, reducing formation of the antibody–prolactin–antibody complexes that generate the measured signal. The result can therefore be falsely low. Request prolactin measurement after serial specimen dilution. This investigation is specifically recommended by the Endocrine Society hyperprolactinemia guideline, recommendation 1.3: https://academic.oup.com/jcem/article/96/2/273/2709487.
Apply it
A patient with amenorrhea, visual-field impairment, and a large sellar mass has only mildly elevated prolactin. A substantially higher dilution-corrected result supports previously masked prolactin excess. If appropriate dilution excludes antigen-excess interference, a nonfunctioning mass with genuine stalk-related hyperprolactinemia remains possible: impaired hypothalamic dopamine delivery removes tonic inhibition of prolactin secretion.
Common pitfall: Stalk-related elevation is a biological effect; the hook effect is an analytical underestimate. Do not diagnose either solely from mass size. Macroprolactin assessment addresses a different problem—measured prolactin containing relatively inactive large molecular forms—and does not substitute for dilution when antigen excess is suspected.
8.Why can one progesterone value confirm ovulation without grading luteal quality?
Progesterone secretion from the corpus luteum is pulsatile and can change substantially over a short interval. An appropriately timed concentration above 3 ng/mL provides presumptive evidence of recent ovulation, but one value cannot establish the adequacy of luteal function. Sampling should be related to the expected next menstrual period rather than a universal calendar day. A low isolated result may reflect timing or a secretory trough rather than a persistent defect.
Apply it
A patient with 35-day cycles has progesterone measured on day 21 and is told her luteal phase is defective. Reconsider whether sampling occurred after ovulation and plan interpretation approximately one week before the expected next period.
Common pitfall: Avoid diagnosing luteal phase deficiency from a single progesterone result or using day 21 for every cycle length. Timing and pulsatility limit the conclusion.
Diagnosis and treatment of luteal phase deficiency (2026) · Fertility evaluation of infertile women (2021)
Reproductive Endocrine Function/Diseasenot stated
9.How should secondary amenorrhea be approached initially?
Pregnancy must be considered first, followed by a history and examination that direct endocrine and anatomic evaluation. TSH, prolactin, and gonadotropin assessment commonly distinguish thyroid disease, hyperprolactinemia, ovarian insufficiency, and central suppression. Estradiol helps interpret gonadotropins. Medication exposure, lactation, weight change, exercise, androgen symptoms, and uterine instrumentation are discriminating clues. An amenorrhea evaluation should localize the disturbance rather than immediately assign every patient an ovarian diagnosis.
Apply it
A previously menstruating patient reports four months without bleeding after a medication change and increased endurance training. Exclude pregnancy, review the medication, assess energy balance, and use targeted hormone testing to distinguish competing central and endocrine causes.
Common pitfall: Amenorrhea is a symptom with several mechanisms. Starting empiric ovulation induction before excluding pregnancy and identifying the underlying disturbance can obscure a treatable diagnosis.
10.How do gonadotropins distinguish central amenorrhea from ovarian insufficiency?
Low estradiol with elevated FSH indicates inadequate ovarian feedback and supports ovarian insufficiency. Low estradiol with low or inappropriately normal gonadotropins instead points toward hypothalamic or pituitary dysfunction. The word inappropriate matters: a normal-range FSH is not physiologically normal when estrogen is very low. Clinical context then separates functional hypothalamic suppression from structural, congenital, medication-related, or other central causes. This localization guides subsequent testing and treatment.
Apply it
Two patients have amenorrhea and low estradiol. One has markedly elevated FSH; the other has low-normal FSH after substantial dietary restriction. Localize the first pattern to ovarian dysfunction and investigate central suppression in the second.
Common pitfall: Do not classify gonadotropins using reference intervals alone. A result must be judged against the ovarian steroid concentration and the feedback response that concentration should produce.
Current evaluation of amenorrhea (2024) · Functional hypothalamic amenorrhea guideline resources (2017)
11.Why is energy restoration central to functional hypothalamic amenorrhea treatment?
Functional hypothalamic amenorrhea reflects suppression of reproductive signaling in association with factors such as inadequate energy availability, excessive exercise, or psychological stress, after other causes are excluded. Treatment addresses the underlying energy imbalance through improved nutrition, reduced exercise when needed, and psychological support. Weight gain may be necessary. Prescribing a combined oral contraceptive solely to create bleeding does not demonstrate recovery of hypothalamic function and can conceal whether spontaneous cycles have returned.
Apply it
A distance runner with negative pregnancy testing, low estradiol, and low-normal gonadotropins requests medication to restart bleeding. Build a nutrition and exercise plan, assess disordered eating and stress, and explain why withdrawal bleeding would not establish physiological recovery.
Common pitfall: A normal body mass index does not exclude low energy availability. Do not dismiss hypothalamic suppression because the patient does not appear underweight.
Functional hypothalamic amenorrhea guideline resources (2017)
12.When does hypothalamic amenorrhea warrant bone-density assessment?
Prolonged hypoestrogenism and nutritional deficits can impair bone health in functional hypothalamic amenorrhea. The Endocrine Society recommends baseline DXA after six or more months of amenorrhea, with earlier assessment when severe nutritional deficiency, another energy-deficit state, or skeletal fragility is suspected. Bone assessment accompanies correction of the underlying problem. It does not replace evaluation for stress injuries, adequate nutrition, or the factors maintaining hypothalamic suppression.
Apply it
An athlete has seven months of amenorrhea and a recent stress fracture. Arrange bone-density assessment while addressing energy availability, nutritional status, and exercise load; the fracture also requires appropriate clinical evaluation independent of the DXA result.
Common pitfall: Do not postpone skeletal evaluation until a patient reaches a particular age. Amenorrhea duration and fragility clues matter, and a normal DXA does not exclude a stress injury.
Functional hypothalamic amenorrhea guideline resources (2017)
13.What criteria support a diagnosis of primary ovarian insufficiency?
Primary ovarian insufficiency is considered before age 40 when spontaneous amenorrhea or irregular menstrual cycles persist for at least four months and FSH is elevated above 25 IU/L. Repeat FSH after four to six weeks is recommended when diagnostic uncertainty remains, rather than automatically requiring two elevated results in every case. Pregnancy and relevant treatment effects must be considered. Low estradiol supports hypoestrogenism but is not independently sufficient to establish the diagnosis.
Apply it
A 33-year-old has six months of irregular or absent periods, negative pregnancy testing, and FSH of 38 IU/L. Assess the overall diagnostic context and repeat FSH if uncertainty remains, rather than rejecting POI because only one result exists.
Common pitfall: Do not use AMH as the primary diagnostic test or require complete permanent cessation of ovarian activity. Intermittent function can occur after POI is diagnosed.
Evidence-based guideline: Premature Ovarian Insufficiency (2025)
14.Why does hormone replacement for POI require separate contraception counseling?
POI does not guarantee permanent absence of ovarian activity, and spontaneous ovulation can occur. Hormone therapy addresses estrogen deficiency and its health consequences but does not provide reliable contraception. Patients who wish to avoid pregnancy need a contraceptive plan in addition to appropriate replacement, or a suitable contraceptive regimen that also addresses their hormonal needs. Patients desiring pregnancy should likewise understand that intermittent activity does not make spontaneous conception predictable.
Apply it
A 29-year-old using estradiol and cyclic progestogen for POI assumes pregnancy is impossible. Explain that replacement is not dependable contraception, clarify her reproductive goals, and choose a contraceptive strategy compatible with her medical history and preferences.
Common pitfall: Do not describe POI as irreversible sterility or assume a withdrawal bleed proves ovulation. Both errors can distort contraceptive and family-building decisions.
Evidence-based guideline: Premature Ovarian Insufficiency (2025)
15.How do breast development, uterine anatomy, testosterone, and chromosomes distinguish causes of primary amenorrhea?
Normal breast development indicates estrogen exposure but does not establish that ovaries or a uterus are present. After confirming uterine absence, distinguish Müllerian agenesis from complete androgen insensitivity. Müllerian agenesis typically involves a 46,XX karyotype, functioning ovaries, and testosterone within the usual female range. Complete androgen insensitivity involves a 46,XY karyotype, testes, and male-range testosterone despite female external genitalia. Testicular anti-Müllerian hormone prevents uterine development; androgen resistance often produces sparse pubic and axillary hair. Aromatization of androgens supports breast development.
Apply it
An adolescent with normal breasts and primary amenorrhea has no uterus on confirmed imaging. Female-range testosterone and a 46,XX result support Müllerian agenesis. Male-range testosterone and a 46,XY result support complete androgen insensitivity, especially with sparse pubic hair. Testosterone measurement and chromosome analysis resolve this differential more directly than assuming estrogen deficiency.
Common pitfall: A difficult ultrasound does not establish uterine absence; confirm anatomy before interpreting the differential. Breast development alone cannot distinguish these diagnoses, and pubic-hair appearance is a supporting cue rather than a replacement for hormonal and chromosome assessment.
16.What can a progestogen-withdrawal test reveal in amenorrhea?
Withdrawal bleeding after a progestogen course suggests that the endometrium has received estrogen and that blood can pass through the outflow tract, supporting anovulation as a mechanism. No bleeding has more than one explanation: insufficient estrogen, endometrial damage, or outflow obstruction. Ultrasound findings and the broader endocrine evaluation help separate these possibilities. The test is therefore a physiological probe with limitations, rather than a standalone diagnosis of ovarian or hypothalamic disease.
Apply it
A patient develops amenorrhea after uterine instrumentation and does not bleed after progestogen withdrawal. Review endometrial thickness and hormone results, then investigate cavity damage when estrogen exposure appears adequate instead of assuming the absent bleed establishes POI.
Common pitfall: An absent withdrawal bleed does not uniquely identify hypoestrogenism. A scarred endometrium or obstructed outflow can produce the same observation despite adequate circulating estrogen.
17.When is macroprolactin testing useful?
Macroprolactin consists largely of prolactin bound in larger complexes that can be detected by laboratory assays but often have limited biological activity. Persistent prolactin elevation that is discordant with symptoms should prompt consideration of macroprolactin, alongside pregnancy, medications, thyroid disease, and other causes. Laboratory assessment can distinguish this pattern from clinically significant monomeric hyperprolactinemia. The result should be interpreted with the patient's menstrual function and symptoms rather than acted on as an isolated number.
Apply it
A regularly menstruating patient has repeated mild prolactin elevation without galactorrhea or other suggestive symptoms. Review reversible causes and request macroprolactin assessment before committing her to a prolactinoma diagnosis and long-term dopamine-agonist treatment.
Common pitfall: Not every elevated total prolactin represents biologically active hormone excess. However, detecting macroprolactin does not excuse ignoring persistent symptoms or an elevated monomeric fraction.
18.How can thyroid disease contribute to menstrual dysfunction?
Thyroid dysfunction can disturb ovulatory function and menstrual patterns. In primary hypothyroidism, increased hypothalamic stimulation can also contribute to elevated prolactin, providing an additional route to reproductive suppression. TSH assessment is therefore useful in amenorrhea, with free thyroxine helping characterize abnormal results. Interpretation must distinguish primary thyroid disease from central dysfunction, where a seemingly normal TSH may be inappropriate for a low free thyroxine concentration and other pituitary findings.
Apply it
A patient with amenorrhea, fatigue, constipation, elevated TSH, and low free thyroxine also has modest prolactin elevation. Recognize primary hypothyroidism as a potential contributor to both abnormalities and reassess reproductive function during appropriate thyroid management.
Common pitfall: Do not diagnose a prolactinoma from modest prolactin elevation before considering hypothyroidism. Also avoid using TSH alone to exclude central thyroid dysfunction when pituitary disease is suspected.
19.How is adult PMOS diagnosed without overusing ovarian imaging?
Adult PMOS, traditionally called PCOS, is diagnosed using two of three features after excluding relevant mimics: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. When irregular cycles and hyperandrogenism are already present, ovarian ultrasound is not required for diagnosis. In adults, AMH can be used within the guideline's diagnostic algorithm as an alternative way to define ovarian morphology, but it is not a standalone diagnostic test.
Apply it
An adult has persistent irregular cycles and clinically significant hirsutism, with pregnancy, thyroid disease, hyperprolactinemia, and relevant androgen disorders excluded. Explain why a normal ovarian ultrasound would not automatically overturn the diagnosis supported by the other two features.
Common pitfall: Polycystic ovarian morphology alone does not establish the syndrome. Avoid transferring adult diagnostic rules directly to adolescents, whose normal maturation can resemble several diagnostic features.
Recommendations from the 2023 international evidence-based PMOS guideline · Monash PCOS Guideline / PMOS Guideline
20.Why does PMOS care extend beyond restoring ovulation?
PMOS combines reproductive and broader health consequences, including increased metabolic risk and endometrial effects of prolonged anovulation. Assessment should address glycemic status, cardiovascular risk factors, psychological wellbeing, and the patient's priorities. Long intervals without progesterone exposure can leave the endometrium exposed to sustained estrogenic stimulation. Cycle regulation or appropriate progestogen therapy can provide protection when pregnancy is not being pursued; fertility treatment alone does not address all these needs.
Apply it
A patient with PMOS requests help with hirsutism and reports only two menstrual periods in the past year. Alongside symptom treatment, assess metabolic health and establish an endometrial-protection plan that matches her current desire to avoid pregnancy.
Common pitfall: Do not define successful care solely by pregnancy or cosmetic improvement. Persistent anovulation and metabolic risks still require attention even when the patient's presenting symptom improves.
Recommendations from the 2023 international evidence-based PMOS guideline
21.Which androgen findings demand evaluation beyond typical PMOS?
Rapid progression of androgenic symptoms or virilization, such as voice deepening or clitoromegaly, warrants evaluation beyond the usual slowly evolving PMOS presentation. The assessment considers ovarian and adrenal androgen sources, exogenous exposure, and other endocrine disorders. Testosterone and adrenal androgen measurements help direct investigation, but symptom tempo and assay quality remain important. A markedly discordant result should be confirmed appropriately rather than interpreted without reference to the clinical phenotype.
Apply it
A patient develops rapidly progressive hirsutism, voice deepening, and new amenorrhea over several months. Investigate an androgen-secreting ovarian or adrenal disorder and medication exposure rather than attributing the presentation to PMOS based on irregular cycles alone.
Common pitfall: Do not let a common diagnosis explain away rapid virilization. Conversely, a single unexpected androgen result requires analytical scrutiny before invasive localization or irreversible treatment.
Current evaluation of amenorrhea (2024) · Recommendations from the 2023 international evidence-based PMOS guideline
22.How does pubertal development help localize reproductive endocrine disease?
Pubertal development depends on coordinated hypothalamic, pituitary, and gonadal function, together with tissue responsiveness to sex steroids. Delayed breast development suggests insufficient estrogen exposure and directs attention to gonadotropin and estradiol patterns. Elevated gonadotropins favor gonadal dysfunction; low or inappropriately normal values suggest a central process. Growth history, chronic illness, nutrition, anosmia, and other pituitary symptoms refine the differential. Pubic hair alone does not demonstrate normal ovarian estrogen production.
Apply it
An adolescent with primary amenorrhea has little breast development and low estradiol. Compare the implications of elevated versus low gonadotropins, and ask about growth, nutrition, chronic disease, and sense of smell before selecting further investigation.
Common pitfall: Adrenarche and gonadarche are distinct processes. Pubic hair can be present despite inadequate ovarian estrogen exposure and should not substitute for assessment of breast development.
Current evaluation of amenorrhea (2024) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
Conception and Pregnancy Physiology/Pathologynot stated
23.How does an implanting pregnancy maintain corpus luteum function?
After ovulation, the corpus luteum produces progesterone that supports secretory endometrial development. Without a pregnancy signal, luteal regression leads to falling steroid concentrations and menstruation. Following implantation, trophoblastic hCG maintains luteal steroid production until placental production becomes sufficient. This explains why luteal function and the circumstances of embryo transfer matter when planning hormonal support. A programmed transfer cycle without ovulation lacks the usual corpus luteum and requires an intentionally provided hormonal environment.
Apply it
A patient asks why progesterone support is prescribed for a programmed frozen embryo transfer despite a positive pregnancy test. Explain that her preparation did not create a corpus luteum and that early support follows the treatment protocol's physiology.
Common pitfall: A positive hCG test does not prove every treatment cycle has adequate endogenous luteal support. Distinguish spontaneous ovulation, stimulated cycles, and programmed transfer preparations.
24.What makes oocyte meiosis important to reproductive aging?
Oocytes begin meiosis before birth and remain arrested for a prolonged interval before resuming maturation. Errors in chromosome segregation can produce aneuploid gametes and embryos, contributing to age-related reproductive decline and pregnancy loss. Ovarian reserve markers describe follicular quantity rather than directly measuring this chromosomal competence. Consequently, a favorable stimulation response at an older reproductive age does not remove age-associated aneuploidy considerations when discussing embryo development, miscarriage, and genetic testing.
Apply it
A 42-year-old produces more oocytes than expected for her age and assumes her miscarriage risk now resembles that of a younger patient. Separate the encouraging oocyte yield from the age-related chromosomal considerations that still influence prognosis.
Common pitfall: Do not use egg number, regular menstruation, or a reassuring AMH value as proof of normal meiotic competence. Quantity and chromosome segregation remain different biological dimensions.
Testing and interpreting measures of ovarian reserve (2020) · Recurrent pregnancy loss (2026)
25.Which fertilization barriers does ICSI bypass?
Conventional fertilization requires sperm to reach and interact with the oocyte, penetrate its surrounding barriers, and fuse with the oocyte membrane. ICSI places a selected sperm directly into the oocyte cytoplasm, bypassing several sperm-number, motility, and penetration limitations. It does not guarantee oocyte activation, normal embryo development, implantation, or a genetically unaffected child. Counseling should distinguish the fertilization problem addressed by the technique from downstream reproductive outcomes it cannot ensure.
Apply it
A couple using surgically retrieved sperm asks whether ICSI guarantees a healthy pregnancy. Explain the specific fertilization barriers it bypasses while preserving separate discussions of sperm-related genetic findings, oocyte competence, embryo development, and implantation.
Common pitfall: Do not describe ICSI as a universal solution for poor embryo development. Successful sperm injection addresses an early technical barrier and cannot correct every gamete or embryo defect.
Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
26.How do cleavage-stage embryos and blastocysts differ?
Early cleavage divisions partition the fertilized oocyte into blastomeres. Continued development leads to compaction and then a blastocyst containing a fluid-filled cavity, inner cell mass, and trophectoderm. Developmental stage affects culture, transfer, cryopreservation, and biopsy decisions. Morphological development provides useful information but does not establish chromosomal normality. A well-expanded blastocyst may still carry aneuploidy or a familial pathogenic variant, while genetic testing itself also has technical and sampling limitations.
Apply it
A patient sees a high-quality blastocyst photograph and asks whether its appearance excludes her familial genetic disorder. Explain the visible developmental structures, then distinguish morphology from the condition-specific information that an appropriately designed genetic test could provide.
Common pitfall: Avoid treating embryo appearance as a genetic diagnosis. Developmental competence, morphology, and the particular genetic question being tested provide related but nonidentical information.
The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025) · Indications and management of preimplantation genetic testing for monogenic conditions (2023)
27.Why can progesterone not establish the location of an early pregnancy?
Progesterone reflects aspects of luteal and pregnancy support, but concentrations overlap among different early-pregnancy outcomes. Even a result concerning for nonviability does not distinguish an intrauterine loss from an ectopic pregnancy. Pregnancy location requires integration of symptoms, serial assessment, and ultrasound rather than interpretation of progesterone alone. Exogenous progesterone further complicates interpretation in fertility treatment. A biochemical marker should therefore answer only the question its biological and analytical limitations allow.
Apply it
A stable patient with a positive hCG test, no identified pregnancy on ultrasound, and low progesterone asks whether an ectopic pregnancy has been excluded. Explain that location remains unresolved and arrange appropriate serial assessment with clear symptom precautions.
Common pitfall: Do not convert evidence about likely viability into proof of location. Low progesterone cannot by itself establish a completed intrauterine miscarriage or exclude an ectopic pregnancy.
Diagnosis and treatment of luteal phase deficiency (2026) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
28.How should pregnancy location be assessed after fertility treatment?
Pregnancy of unknown location is a temporary classification when pregnancy testing is positive but transvaginal ultrasound identifies neither an intrauterine nor an extrauterine pregnancy. For a stable patient, reassess symptoms and obtain a second serum hCG measurement as near as possible to 48 hours after the first, but no earlier. NICE NG126 uses a rise greater than 63% to identify a likely developing intrauterine pregnancy, while explicitly retaining the possibility of ectopic pregnancy. Offer repeat transvaginal ultrasound 7–14 days later; consider earlier scanning when hCG is at least 1,500 IU/L. These are NICE pathway thresholds, not proof of location. A fall greater than 50% suggests a pregnancy unlikely to continue: NICE advises a urine pregnancy test 14 days after the second blood test, with review within 24 hours if positive. A rise below 63% or fall below 50% warrants clinical review within 24 hours. New or worsening symptoms override laboratory trends and require prompt reassessment, including emergency care when indicated. Provide written precautions and 24-hour access instructions.
Apply it
A stable patient has hCG of 800 IU/L and an inconclusive scan. Approximately 48 hours later, hCG is 1,400 IU/L and symptoms remain mild and unchanged. The 75% rise meets NICE's likely-developing-pregnancy pathway: arrange transvaginal ultrasound 7–14 days later, considering earlier scanning as appropriate. Explain that location remains unconfirmed. If she develops worsening unilateral pain, shoulder-tip pain, faintness, or collapse before that appointment, arrange immediate assessment rather than waiting for the scheduled scan or another hCG result.
Common pitfall: hCG trends assess trophoblastic proliferation and cannot establish pregnancy location; even a reassuring rise does not exclude ectopic pregnancy. After ART, an identified intrauterine pregnancy also does not exclude a concurrent ectopic gestation. Persistent focal pain or an extraovarian adnexal mass warrants assessment for heterotopic pregnancy.
Diagnosis of viable intrauterine pregnancy and of tubal ectopic pregnancy | Ectopic pregnancy and miscarriage: diagnosis and initial management | Guidance | NICE · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
29.What can genetic testing of miscarriage tissue clarify?
Genetic analysis of miscarriage tissue can identify a chromosomal explanation for a particular loss and help guide subsequent counseling. Interpretation depends on the platform, specimen quality, and the possibility of maternal cell contamination. An aneuploid result may explain that pregnancy's outcome without establishing a recurrent parental disorder. Conversely, a euploid result does not prove a specific uterine, endocrine, or immunologic cause. Tissue testing complements clinical evaluation rather than replacing it.
Apply it
A patient with recurrent losses receives a normal female tissue result. Before concluding the embryo was definitively euploid, review whether the laboratory assessed maternal cell contamination and whether the selected test adequately addressed the relevant chromosomal question.
Common pitfall: Do not assume every normal female result represents fetal tissue. Also avoid treating one aneuploid loss as proof that all previous and future losses share the same cause.
30.When should recurrent pregnancy loss prompt structured evaluation?
Current ASRM guidance recognizes recurrent pregnancy loss after two or more pregnancy losses and includes pregnancies documented by hCG, rather than restricting recognition to ultrasound-confirmed clinical pregnancies. Confirm the history and distinguish losses from ectopic or molar pregnancies, which follow different evaluation pathways. Assessment considers genetic, uterine, endocrine, and appropriately selected immunologic factors. The goal is to identify actionable findings while explaining that an evaluation may not establish a single cause.
Apply it
A patient reports one ultrasound-confirmed miscarriage and one earlier hCG-confirmed loss before a sac was visible. Document both histories carefully and consider structured RPL evaluation rather than dismissing the earlier loss solely because ultrasound confirmation was absent.
Common pitfall: Do not automatically apply an older clinical-pregnancy-only definition. Equally, a positive test with unresolved location requires appropriate pregnancy assessment before its outcome is classified.
31.Which findings justify antithrombotic treatment or consideration of progesterone in recurrent pregnancy loss?
Traditional antiphospholipid syndrome classification criteria inform clinical assessment by requiring a qualifying clinical event and persistent qualifying antibodies. Obstetric events include three consecutive unexplained losses before 10 weeks after excluding maternal anatomic and hormonal causes and parental chromosomal causes; an unexplained death of a morphologically normal fetus at or after 10 weeks; or delivery of a morphologically normal infant before 34 weeks because of eclampsia, severe preeclampsia, or recognized placental insufficiency. Qualifying laboratory findings are lupus anticoagulant detected by accepted laboratory criteria; anticardiolipin IgG or IgM above 40 GPL/MPL units or above the 99th percentile; or anti-beta-2-glycoprotein I IgG or IgM above the 99th percentile. The qualifying antibody finding must be confirmed on at least two occasions at least 12 weeks apart. Aspirin plus heparin is indicated for established obstetric APS; unexplained RPL alone does not establish an anticoagulation indication.
Apply it
A patient with recurrent losses and one low-positive antibody result needs assessment of the clinical history, the antibody type and threshold, and persistence before being labeled with APS. A low-positive anticardiolipin result below both qualifying thresholds does not meet the traditional laboratory criterion even if repeated. If the evaluation remains unexplained, discuss prognosis and supportive care. Vaginal progesterone may be considered through shared decision-making for early-pregnancy bleeding and/or recurrent unexplained miscarriage, while explaining that overall benefit remains uncertain.
Common pitfall: These are traditional classification criteria informing clinical assessment, not proof that every recurrent loss is thrombotic. Do not infer APS from miscarriage history alone or prescribe heparin empirically for unexplained RPL. An isolated progesterone concentration does not establish a progesterone-responsive cause of loss. Thyroid hormone should address an established thyroid indication rather than serve as routine miscarriage supplementation.
Fertility/Infertilitynot stated
32.When should an infertility evaluation begin?
For patients without a known infertility-associated condition, evaluation generally begins after 12 months of regular unprotected intercourse when younger than 35 and after six months at age 35 or older. More immediate assessment may be appropriate over age 40. Evaluation should begin without delay when history suggests anovulation, tubal disease, significant male factor, or another condition affecting fertility. These intervals guide evaluation timing and do not require delaying care when a problem is already evident.
Apply it
A 32-year-old has attempted conception for four months but has menstrual intervals of several months. Begin evaluation of ovulatory dysfunction now, rather than asking her to complete a year of attempts before investigating an already apparent fertility-related condition.
Common pitfall: Do not apply the 12-month interval rigidly to every patient. Age, menstrual abnormalities, relevant medical treatment, and known reproductive disease can justify earlier assessment.
33.Why should both reproductive partners be evaluated concurrently?
Infertility can arise from female factors, male factors, or a combination, so evaluation of a contributing sperm partner should occur alongside the other partner's assessment. A reproductive history and semen analysis can identify problems that change treatment selection and prevent unnecessary procedures. Semen results vary, and abnormal findings may require confirmation and specialist assessment. Prior paternity does not exclude a current male factor, particularly after medication changes, illness, surgery, or new exposures.
Apply it
A couple presents after a year of unsuccessful conception. Although the sperm partner previously fathered a child, obtain his current reproductive and medication history and semen analysis while assessing ovulation, reproductive anatomy, and other factors in the other partner.
Common pitfall: Do not complete an extensive female evaluation before considering the sperm partner. Previous fertility in either partner does not establish normal current reproductive function.
Fertility evaluation of infertile women (2021) · Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I (2020)
34.How should ovulatory function be assessed efficiently?
A menstrual history often provides useful evidence of ovulation, particularly with regular predictable cycles. When confirmation is needed, progesterone should be timed approximately one week before the expected next period. Urinary LH testing detects a surge preceding ovulation but does not directly demonstrate follicular rupture, and interpretation can be difficult in PMOS. Select testing to answer an unresolved clinical question rather than automatically ordering multiple overlapping measures for every patient.
Apply it
A patient has predictable 32-day cycles but needs biochemical confirmation of ovulation. Schedule progesterone relative to her expected next menses instead of automatically choosing day 21, and explain that one result will not measure overall luteal quality.
Common pitfall: Do not equate an LH-positive urine test with guaranteed ovulation or use a fixed progesterone collection day despite substantial differences in menstrual cycle length.
35.How should apparent proximal tubal obstruction on HSG be interpreted?
Hysterosalpingography assesses tubal patency, but apparent proximal obstruction can result from transient spasm, mucus, or technical factors rather than fixed occlusion. Bilateral proximal obstruction therefore warrants careful confirmation before a definitive treatment decision. Repeat assessment or selective tubal evaluation may clarify the finding in an appropriate patient. HSG also does not fully characterize every pelvic adhesion or endometrial lesion, so its result must be interpreted within the broader infertility evaluation.
Apply it
A patient without a strong tubal-disease history has bilateral proximal blockage reported during a painful HSG. Discuss possible artifact and confirm the finding appropriately before counseling that both tubes are permanently blocked and IVF is the only option.
Common pitfall: Do not treat every absent spill as irreversible tubal disease. Conversely, a technically plausible artifact should prompt clarification rather than an assumption that the tubes are normal.
Role of tubal surgery in the era of assisted reproductive technology (2021) · Fertility evaluation of infertile women (2021)
36.When is letrozole preferred for anovulatory infertility in PMOS?
For anovulatory infertility associated with PMOS when no other infertility factor is present, letrozole is the recommended first-line pharmacologic ovulation-induction treatment. Aromatase inhibition reduces estrogen synthesis temporarily, altering feedback and promoting endogenous gonadotropin support for follicular development. Treatment selection still requires pregnancy exclusion and appropriate assessment of other reproductive factors. Inducing ovulation cannot overcome an unrecognized severe sperm factor or bilateral tubal occlusion, so the indication must match the complete clinical picture.
Apply it
A patient with PMOS has infrequent ovulation, patent tubes, and a partner with reassuring semen testing. Discuss letrozole as first-line pharmacologic induction rather than moving immediately to IVF solely because spontaneous cycles are irregular.
Common pitfall: Do not extrapolate this first-line recommendation to every infertility diagnosis. Its strongest application is anovulatory PMOS without another factor requiring a different treatment pathway.
Recommendations from the 2023 international evidence-based PMOS guideline
37.How can azoospermia reflect either obstruction or impaired sperm production?
Absent sperm in the ejaculate can result from impaired production or a failure of transport. History, examination, semen characteristics, testicular size, and endocrine findings help distinguish these mechanisms. Small testes with elevated FSH suggest impaired spermatogenesis, while normal-sized testes and findings such as absent vasa can support obstruction. No single feature is perfect. Specialist assessment determines the appropriate genetic evaluation, potential reconstructive options, and whether sperm retrieval with assisted reproduction is feasible.
Apply it
Two men have confirmed azoospermia. One has small testes and elevated FSH; the other has normal-sized testes and absent vasa. Use these patterns to frame different mechanisms and investigations rather than offering identical empiric hormonal treatment.
Common pitfall: Do not interpret azoospermia as proof that no sperm exist anywhere in the reproductive tract. Ejaculatory absence, obstruction, and testicular production failure require different evaluation.
Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I (2020)
38.Why can exogenous testosterone cause male infertility?
Exogenous testosterone suppresses hypothalamic-pituitary signaling and lowers gonadotropin support of the testes. Serum testosterone may appear adequate while intratesticular conditions needed for spermatogenesis deteriorate, producing oligospermia or azoospermia. Testosterone monotherapy should therefore not be prescribed to a man interested in current or future fertility. Management requires review of the original indication and reproductive goals, with specialist-directed alternatives or recovery planning rather than simply increasing the testosterone dose.
Apply it
A man using injectable testosterone develops azoospermia despite a normal serum testosterone concentration. Explain the negative-feedback mechanism, coordinate fertility-focused endocrine assessment, and avoid reassuring him that a normal blood testosterone level proves normal sperm production.
Common pitfall: Do not use serum testosterone as a surrogate for intratesticular testosterone or spermatogenesis. A treatment that improves androgen symptoms can simultaneously impair fertility.
Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II
39.Why does congenital absence of the vasa deferentia trigger genetic counseling?
Congenital vasal agenesis can be associated with CFTR variants, making the finding relevant to both the man's diagnosis and potential offspring. Appropriate CFTR testing and partner evaluation help define reproductive risk before use of retrieved sperm. The joint male-infertility guidance also recommends renal ultrasonography in vasal agenesis because associated urinary tract anomalies may be present. Sperm retrieval can address transport obstruction but does not remove a heritable risk identified during the evaluation.
Apply it
A man with absent vasa plans sperm retrieval and ICSI. Arrange CFTR-related assessment and appropriate partner counseling, and include renal imaging rather than limiting the consultation to whether sperm can be obtained.
Common pitfall: Do not assume ICSI eliminates the need to investigate the cause of obstruction. Technical access to sperm and the offspring's inherited risk are separate counseling questions.
Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I (2020)
40.How should reconstruction versus sperm retrieval with IVF/ICSI be selected for acquired reproductive-tract obstruction?
For acquired vasal or epididymal obstruction, microsurgical reconstruction and sperm retrieval followed by IVF/ICSI are alternative family-building strategies. Reconstruction seeks to restore sperm to the ejaculate and permit conception through intercourse; retrieval bypasses the obstruction but requires IVF with oocyte retrieval and usually ICSI. Selection depends on the obstruction's site and reconstructability, surgical expertise, desired family size, and the other partner's fertility potential. Reconstruction may be attractive when the partner has favorable fertility potential, particularly if several children are desired. Significant female infertility or limited reproductive time may favor retrieval with IVF/ICSI.
Apply it
After vasectomy, a man and his younger partner with reassuring fertility assessment may reasonably consider reversal. If his partner instead has bilateral tubal disease requiring IVF, reconstruction does not correct that separate barrier; sperm retrieval coordinated with IVF/ICSI may better match the couple's combined diagnoses. Advanced reproductive age or diminished ovarian reserve also changes the importance of treatment delay.
Common pitfall: Restored ductal patency does not guarantee pregnancy, and successful sperm retrieval does not guarantee live birth. Avoid selecting a male procedure without evaluating the other partner. Discuss surgical burden, ovarian treatment burden, time, costs, and the possibility of persistent or recurrent obstruction.
Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II · Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I (2020)
41.What physiological process causes clinically significant OHSS?
OHSS involves increased vascular permeability following ovarian stimulation, with fluid moving out of the circulation into third spaces. Ovarian mediators, including vascular endothelial growth factor, are influenced by luteotropic stimulation. Ascites can therefore coexist with reduced effective intravascular volume, hemoconcentration, and thrombotic risk. A large follicular response and high ovarian reserve markers help identify risk before symptoms occur. Prevention is preferable to relying on recognition after fluid shifts and organ effects develop.
Apply it
After stimulation, a patient develops increasing abdominal distension, reduced urine output, and rapid weight gain. Recognize that visible fluid accumulation does not establish adequate circulating volume, and assess promptly for OHSS severity and associated complications.
Common pitfall: Do not interpret ascites as simple fluid excess or reassure solely because peripheral edema is present. Third spacing can coexist with clinically important intravascular depletion.
Prevention of moderate and severe ovarian hyperstimulation syndrome (2023)
42.How can stimulation protocol and trigger selection reduce OHSS risk?
OHSS prevention begins with identifying high responders and individualizing gonadotropin exposure. A GnRH antagonist protocol permits use of a GnRH agonist trigger, which reduces prolonged luteotropic stimulation compared with an hCG trigger. In a high-risk cycle, trigger choice should be integrated with the embryo-transfer plan and other indicated preventive measures. Adding hCG back into a strategy can reintroduce risk, so the complete regimen matters more than the name of a single component.
Apply it
A patient with high AMH and a very large developing follicle cohort is in an antagonist cycle. Reassess trigger and transfer plans before maturation, explaining why an agonist trigger and embryo cryopreservation may form a coordinated prevention strategy.
Common pitfall: Do not assume an antagonist protocol alone eliminates OHSS. Actual follicular response, trigger exposure, additional hCG, and pregnancy-related stimulation all influence residual risk.
Prevention of moderate and severe ovarian hyperstimulation syndrome (2023)
43.Why does a freeze-only strategy reduce late OHSS?
A fresh pregnancy can supply endogenous hCG that sustains ovarian stimulation and contributes to late OHSS. Cryopreserving embryos and postponing transfer avoids that pregnancy-related stimulus during the stimulated cycle. This strategy is especially useful for patients with a high response or other important OHSS risk indicators. It reduces risk but does not erase effects of prior triggering or prevent every early complication, so symptom assessment and an appropriate prevention plan remain necessary.
Apply it
A high responder wants immediate transfer because embryos are available. Explain how a fresh pregnancy could prolong stimulation of the enlarged ovaries and why postponing transfer can improve safety without implying that embryo freezing guarantees absence of OHSS.
Common pitfall: Do not promise that freeze-only prevents all OHSS. It principally removes the fresh-pregnancy contribution and must be combined with appropriate stimulation and trigger decisions.
Prevention of moderate and severe ovarian hyperstimulation syndrome (2023)
44.How many euploid embryos should usually be transferred at once?
ASRM/SART guidance recommends transfer of one euploid embryo regardless of patient age. Transferring additional embryos increases the chance of multifetal gestation and its associated maternal and neonatal risks; it should not be justified simply by the recipient's age or desire to complete a family quickly. Counseling should distinguish the outcome of a single transfer from cumulative opportunities across successive transfers. Embryo euploidy informs transfer planning but does not guarantee implantation or birth.
Apply it
A 43-year-old has two euploid blastocysts and asks to transfer both because of her age. Recommend single-embryo transfer and discuss sequential opportunities, while explaining that her age does not override the one-euploid-embryo recommendation.
Common pitfall: Do not use advanced recipient age as an automatic reason to transfer two euploid embryos. The risks of twins remain relevant despite a history of infertility.
Guidance on the limits to the number of embryos to transfer (2021)
45.Which age matters when applying donor-oocyte embryo-transfer guidance?
When applying embryo-transfer guidance to donor-oocyte cycles, the age of the oocyte donor is relevant to embryo-related prognosis rather than simply the recipient's chronological age. Recipient health remains crucial because it influences pregnancy tolerance and obstetric risk. These are different dimensions of the decision. A healthy-appearing older recipient does not make multiple gestation harmless, and a younger donor does not eliminate the need for recipient medical assessment or informed third-party reproduction counseling.
Apply it
A 46-year-old recipient will use embryos from a young oocyte donor. Base embryo-number counseling on the donor-oocyte context while independently assessing the recipient's medical suitability and explaining the additional burden of multifetal pregnancy.
Common pitfall: Do not substitute recipient age for oocyte age when considering embryo prognosis, or substitute donor youth for an assessment of the recipient's pregnancy-related medical risks.
Guidance on the limits to the number of embryos to transfer (2021)
46.Why can fertility-preservation stimulation begin outside the early follicular phase?
Random-start ovarian stimulation permits initiation at different menstrual-cycle stages, reducing the delay associated with waiting for the next early follicular phase. This is particularly valuable before time-sensitive gonadotoxic treatment. The plan must be coordinated with the treating oncology or medical team, and an aromatase inhibitor may be incorporated when limiting estrogen exposure is appropriate. Random start changes scheduling flexibility; it does not remove the time needed for stimulation or guarantee an adequate oocyte yield.
Apply it
A patient newly diagnosed with cancer presents during the luteal phase and has a limited interval before chemotherapy. Arrange urgent fertility-preservation assessment and consider random-start stimulation instead of automatically waiting for another menstrual period.
Common pitfall: Do not equate random start with instantaneous preservation or permission to delay essential cancer treatment. The available treatment window and the patient's clinical condition still govern feasibility.
Fertility preservation in patients with medical indications (2026)
47.When is ovarian tissue cryopreservation appropriate, and what cancer-specific limitation affects later transplantation?
Ovarian tissue cryopreservation is an established fertility-preservation method rather than an experimental procedure. It is particularly relevant before puberty or when the treatment window cannot accommodate ovarian stimulation. Oocyte and embryo cryopreservation require stimulation and retrieval; random-start stimulation can reduce cycle-related delay when time permits. Selection depends on age, expected gonadotoxicity, diagnosis, available time, and reproductive goals. A major limitation concerns subsequent tissue transplantation: tissue containing malignant cells could reintroduce cancer. Suitability therefore requires diagnosis-specific assessment with oncology, considering the likelihood of ovarian involvement.
Apply it
For a prepubertal patient facing gonadotoxic therapy, ovarian tissue cryopreservation offers an established option when mature-oocyte preservation is unsuitable. For a patient with a malignancy that may involve ovarian tissue, distinguish the feasibility of tissue collection from the safety of future transplantation. Explain how the cancer diagnosis may limit later use rather than assuming every malignancy carries the same risk.
Common pitfall: Do not describe ovarian tissue cryopreservation as experimental or assume that stored tissue can always be safely transplanted. Conversely, cancer is not a blanket contraindication across all diagnoses. Ovarian suppression does not replace established cryopreservation methods, and preserved tissue, oocytes, embryos, or sperm cannot guarantee a future live birth.
Fertility preservation in patients with medical indications (2026)
Anatomic Reproductive Disordersnot stated
48.Why should a communicating hydrosalpinx be addressed before IVF transfer?
A hydrosalpinx can impair IVF outcomes even though IVF bypasses the tube for fertilization. Fluid from a communicating damaged tube can reach the uterine cavity and adversely affect implantation. Salpingectomy or proximal tubal occlusion can improve outcomes in appropriately selected patients before embryo transfer. Planning must account for surgical feasibility, adhesions, and preservation of ovarian blood supply. The decision concerns the tube's effect on the uterine environment, not merely whether an oocyte can traverse it.
Apply it
A patient preparing for IVF has an ultrasound-visible hydrosalpinx communicating with the uterus. Discuss salpingectomy or proximal occlusion before transfer, while reviewing operative difficulty and ovarian considerations instead of dismissing the tube because fertilization will occur in the laboratory.
Common pitfall: Do not assume IVF makes tubal pathology irrelevant. A damaged communicating tube can affect implantation even when sperm and oocyte never need to meet inside it.
Role of tubal surgery in the era of assisted reproductive technology (2021)
49.When should an endometrioma be operated on before ART?
Routine endometrioma surgery before ART is not recommended solely to improve live-birth rates because benefit has not been demonstrated and surgery can reduce ovarian reserve. Surgery may still be considered for pain or to improve access to follicles, with other concerning features requiring appropriate assessment. The decision balances symptoms, imaging, previous surgery, reserve, and treatment goals. Hormonal suppression may treat endometriosis-related pain but does not itself improve fertility while suppressing ovulation.
Apply it
A patient with a stable, typical, painless endometrioma and diminished reserve is preparing for IVF. Discuss proceeding without routine cystectomy when access is adequate, while explaining that new suspicious features or significant symptoms would change the decision.
Common pitfall: Do not equate removal of visible disease with improved ART success. Repeat ovarian surgery can sacrifice functioning tissue, and pain-treatment goals may differ from immediate fertility goals.
50.What anatomical distinction separates adenomyosis from endometriosis?
Adenomyosis consists of endometrial glands and stroma within the myometrium. Endometriosis is characterized by endometrium-like epithelium and/or stroma outside the endometrium and myometrium, consistent with ESHRE terminology. The myometrial boundary is essential: defining endometriosis merely as tissue outside the uterine cavity would incorrectly encompass adenomyosis. Adenomyosis may be associated with heavy menstrual bleeding, dysmenorrhea, and supportive myometrial imaging findings. Endometriosis may involve pelvic peritoneum, ovaries, or other extrauterine sites. The conditions can coexist, and symptoms alone do not establish anatomical location.
Apply it
A patient with heavy painful menstruation and diffuse myometrial abnormalities may have adenomyosis. A separate ovarian endometrioma represents endometriosis. An intracavitary polyp occupies a third anatomical compartment. Mapping each finding explains why hysteroscopic removal of a polyp would not remove adenomyosis within the uterine muscle or treat an ovarian endometrioma.
Common pitfall: Do not classify every focus outside the endometrial cavity as endometriosis. Distinguish cavity, myometrium, and sites outside both endometrium and myometrium. Imaging and clinical assessment should also consider coexisting fibroids and other causes of bleeding or pain.
The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025) · Fertility evaluation of infertile women (2021) · ESHRE Guideline: Endometriosis (2022)
51.Why does evaluation of a uterine anomaly require the external contour?
Different congenital uterine anomalies can produce similar appearances within the endometrial cavity while having different external fundal contours. Imaging that characterizes both the cavity and outer uterine shape helps distinguish a septate configuration from a fusion anomaly such as a bicornuate uterus. Three-dimensional ultrasonography or MRI can provide relevant anatomical information. Accurate classification precedes management because a procedure appropriate for an intracavitary septum is not automatically appropriate for a differently formed uterine fundus.
Apply it
An HSG shows two divergent endometrial cavities in a patient with reproductive concerns. Obtain imaging that defines the external fundal contour before offering septum surgery, since the cavity image alone cannot fully classify the congenital anomaly.
Common pitfall: Do not diagnose a septate uterus solely from an HSG or hysteroscopic cavity view. Both can leave the crucial external fundal anatomy unresolved.
Fertility evaluation of infertile women (2021) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
52.When should intrauterine adhesions be suspected?
Intrauterine adhesions can follow injury to the endometrial cavity, particularly after pregnancy-related instrumentation. New scant menstruation or amenorrhea, infertility, or recurrent loss after such an event raises suspicion for Asherman syndrome. The endocrine axis may remain functional, so normal hormone results do not exclude the diagnosis. Cavity assessment identifies structural damage, and hysteroscopy allows direct evaluation and treatment planning. Management aims to restore anatomy while minimizing further injury to the remaining endometrium.
Apply it
A patient reports nearly absent menses beginning after evacuation of retained pregnancy tissue, despite previously regular cycles. Investigate the uterine cavity rather than repeatedly prescribing endocrine treatment when the chronology suggests a new structural endometrial problem.
Common pitfall: Do not assume amenorrhea always means ovarian hormone failure. Endometrial scarring can prevent normal bleeding even when ovarian function and estrogen exposure are preserved.
Current evaluation of amenorrhea (2024) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
53.How does fibroid-related cavity distortion change fertility management?
Describe each fibroid's location, size, symptoms, and relationship to the endometrial cavity. Myomectomy may be considered for cavity-distorting myomas to improve pregnancy rates. For hysteroscopic removal of submucosal myomas, evidence supports improved clinical pregnancy rates, while effects on live birth and miscarriage remain uncertain. Surgery solely to improve reproductive outcomes is generally not advised for asymptomatic non-cavity-distorting lesions. An exception may arise when major pelvic distortion makes the ovaries inaccessible for oocyte retrieval. Symptoms can provide a separate treatment indication.
Apply it
Sonohysterography confirms that one lesion projects into and distorts the cavity, while a similarly sized subserosal fibroid leaves the cavity unchanged. Discuss removal of the cavity-distorting lesion as a potential means of improving pregnancy rates. Observation is generally appropriate for the asymptomatic subserosal lesion unless it creates a separate problem, such as obstructing planned retrieval access.
Common pitfall: Equal diameters do not imply equal reproductive effects. Do not promise that myomectomy will prevent miscarriage or improve live birth merely because clinical pregnancy evidence is favorable. Balance a defined indication against surgical morbidity, adhesion formation, and treatment delay; fibroid presence alone does not prove the cause of infertility.
Fertility evaluation of infertile women (2021) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025) · Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline (2017) | American Society for Reproductive Medicine | ASRM
54.How should a suspected endometrial polyp be characterized?
An endometrial polyp is a focal lesion arising from the endometrial lining and should be distinguished from a submucosal fibroid, diffuse thickening, and imaging artifact. Sonohysterography can improve delineation of intracavitary abnormalities, while hysteroscopy permits direct visualization and targeted removal when indicated. Management depends on symptoms, reproductive context, and relevant clinical risks. Identifying a possible polyp does not establish that it explains every episode of bleeding, infertility, or pregnancy loss.
Apply it
A patient with intermenstrual spotting has a possible focal lesion on routine ultrasound. Use cavity-focused assessment to define the finding and plan targeted management rather than assuming the image establishes the lesion's type or reproductive significance.
Common pitfall: Do not rely on a nonspecific thickened endometrial stripe to diagnose a polyp. Focal anatomy and appropriate visualization are more informative than thickness alone.
Fertility evaluation of infertile women (2021) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
Reproductive Geneticsnot stated
55.How is autosomal recessive reproductive risk calculated?
When both reproductive partners carry a pathogenic variant for the same autosomal recessive condition, each pregnancy generally has a 25% probability of an affected child, a 50% probability of an unaffected carrier, and a 25% probability of an unaffected noncarrier. These probabilities recur independently with each conception. The calculation assumes the variants and disease mechanism have been correctly characterized. Different genes, uncertain variants, and condition-specific complexities require a different interpretation rather than automatic use of the same calculation.
Apply it
Both partners carry confirmed pathogenic variants for the same recessive disorder and already have one unaffected child. Explain that the next pregnancy still has a one-in-four affected risk and discuss condition-specific testing or reproductive options.
Common pitfall: Do not reduce the next pregnancy's risk because previous children were unaffected. Also distinguish carrying variants in the same disease gene from unrelated positive carrier-screening findings.
56.What does autosomal dominant inheritance predict about transmission?
A heterozygous parent with an autosomal dominant pathogenic variant generally has a 50% probability of transmitting that variant in each pregnancy. Transmission probability is different from certainty about disease severity or age at onset. Reduced penetrance and variable expression can mean that relatives carrying the same variant have different clinical findings. Counseling should therefore distinguish the chance of inheriting a variant from the range of outcomes associated with it.
Apply it
A parent with a mild manifestation of a dominant condition assumes an affected child would also have mild disease. Explain the one-in-two transmission probability and review whether variable expression or reduced penetrance limits prediction of the child's phenotype.
Common pitfall: Do not interpret a mildly affected parent as a guarantee of mild offspring disease. Mendelian transmission can be predictable while clinical expression remains uncertain.
MedlinePlus Genetics: Inheritance risk assessment · Indications and management of preimplantation genetic testing for monogenic conditions (2023)
57.Why does a negative carrier screen leave residual risk?
Carrier screening evaluates a defined set of genes and detectable variant types; it does not identify every possible cause of inherited disease. A negative result lowers the estimated carrier probability but does not reduce it to zero. Interpretation depends on test coverage, technical sensitivity, ancestry where relevant, and family history. A known familial pathogenic variant requires confirmation that the chosen test actually assesses it, rather than assuming a broad panel necessarily resolves the family's specific risk.
Apply it
One partner carries a pathogenic recessive variant and the other has a negative screening panel. Review the second partner's assay coverage and residual risk before reassuring the couple, particularly if a relevant family history suggests targeted testing is needed.
Common pitfall: Do not describe a negative panel as genetic clearance. Screening breadth and detection sensitivity are finite, and a family-specific question may require a different test.
Indications and management of preimplantation genetic testing for monogenic conditions (2023) · MedlinePlus Genetics: Inheritance risk assessment
58.Why are karyotype and chromosomal microarray not interchangeable?
A karyotype can identify large chromosomal changes and balanced structural rearrangements, while chromosomal microarray primarily identifies gains and losses of genomic material at higher resolution. A balanced rearrangement may therefore be present despite a normal microarray because no net copy-number change exists. In reproductive counseling, the relevant question determines the assay: investigating a parental balanced translocation differs from examining miscarriage tissue for aneuploidy or smaller imbalances. Platform-specific limitations must accompany the result.
Apply it
A patient with recurrent pregnancy loss has a normal copy-number microarray and assumes a balanced parental translocation is excluded. Explain why a copy-neutral rearrangement may require karyotype-based evaluation and choose testing according to the clinical question.
Common pitfall: Higher resolution does not mean one test detects every category of genetic change. A technically excellent copy-number assay can still miss a balanced structural rearrangement.
Recurrent pregnancy loss (2026) · The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
59.How do PGT-M, PGT-A, and PGT-SR answer different questions?
PGT-M targets a particular monogenic condition, PGT-A assesses chromosomal aneuploidy, and PGT-SR addresses reproductive risks associated with structural chromosomal rearrangements. These approaches are not interchangeable. A euploid embryo can still carry a familial pathogenic single-gene variant, and testing for one monogenic condition does not establish general chromosomal normality. Counseling should identify the intended question, the laboratory method, the possible results, and any additional testing needed before interpreting an embryo as suitable for transfer.
Apply it
A couple with a known dominant pathogenic variant has embryos reported as euploid after PGT-A. Explain that the aneuploidy result does not establish whether the embryos inherited their familial variant and discuss condition-specific PGT-M.
Common pitfall: Do not use the word tested as though it means free of every genetic disorder. Each PGT strategy has a defined target and technical boundaries.
Indications and management of preimplantation genetic testing for monogenic conditions (2023) · Recurrent pregnancy loss (2026)
60.Why is prenatal confirmation offered after PGT-M?
PGT-M analyzes limited embryonic material and has technical limitations, including allele dropout, in which one allele fails to amplify. Linkage analysis and other laboratory safeguards reduce error but do not make it impossible. Prenatal diagnostic testing should therefore be offered to confirm the relevant result after pregnancy is established. Routine aneuploidy screening may not assess the familial monogenic condition. Counseling before IVF should explain both the embryo-testing strategy and the subsequent confirmation options.
Apply it
A pregnancy follows transfer of an embryo classified as unaffected for a familial disorder by PGT-M. Explain the remaining technical uncertainty and offer targeted prenatal diagnosis rather than assuming routine cell-free DNA screening will confirm the monogenic result.
Common pitfall: Do not describe PGT-M as definitive prenatal diagnosis or substitute an unrelated screening test for confirmation. The confirmatory test must address the family's actual pathogenic variant.
Indications and management of preimplantation genetic testing for monogenic conditions (2023)
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Localize endocrine abnormalities through feedback physiology before choosing additional tests or treatment.
- Interpret hormone assays using cycle timing, concurrent hormones, medication exposure, and analytical limitations.
- Distinguish ovarian quantity, oocyte competence, fertilization, implantation, and cumulative treatment opportunities.
- Connect infertility treatment selection to ovulation, tubal anatomy, sperm findings, age, and patient goals.
- Build OHSS prevention into stimulation, trigger, and embryo-transfer decisions.
- Separate pregnancy viability from location and maintain suspicion for heterotopic pregnancy after ART.
- Match reproductive surgery to anatomy while considering ovarian reserve, tissue injury, and reproductive goals.
- Explain genetic transmission, residual risk, assay scope, and confirmation after embryo testing.
A practical preparation plan
1. Map the complete competency outline
Use the six-domain ABOG outline to identify additional topics beyond these selected concepts, including adrenal provocative testing, endocrine disorders in pregnancy, procedural complications, third-party reproduction, and complex medical care.
2. Practise endocrine localization
For each amenorrhea case, predict pregnancy status, estradiol, gonadotropins, prolactin, thyroid findings, and uterine anatomy before reading the explanation. State which finding would change your leading diagnosis.
3. Construct treatment decisions
Compare cases that differ in one decisive feature: anovulation versus tubal occlusion, high response versus low reserve, painless endometrioma versus difficult follicle access, or euploid embryos versus untested embryos.
4. Complete and explain the questions
Answer all 20 drills, then explain why each alternative is less appropriate. Classify errors as physiology, test interpretation, indication selection, or overgeneralization rather than using the score to predict certification performance.
5. Rehearse concise counseling
Use the flashcards to give brief explanations of uncertainty, residual genetic risk, treatment limitations, and safety tradeoffs. Revisit the relevant clinical reference when your explanation cannot identify a mechanism and a discriminating cue.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABOG subspecialty-certification exam blueprint listing
- ABOG Reproductive Endocrinology and Infertility competency blueprint
- The reproductive endocrinology and infertility subspecialist: definition, training, and scope of practice in the United States (2025)
- Testing and interpreting measures of ovarian reserve (2020)
- Current evaluation of amenorrhea (2024)
- Functional hypothalamic amenorrhea guideline resources (2017)
- Evidence-based guideline: Premature Ovarian Insufficiency (2025)
- Recommendations from the 2023 international evidence-based PMOS guideline
- Monash PCOS Guideline / PMOS Guideline
- Diagnosis and treatment of luteal phase deficiency (2026)
- Recurrent pregnancy loss (2026)
- Fertility evaluation of infertile women (2021)
- Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II
- Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I (2020)
- Prevention of moderate and severe ovarian hyperstimulation syndrome (2023)
- Guidance on the limits to the number of embryos to transfer (2021)
- Fertility preservation in patients with medical indications (2026)
- Role of tubal surgery in the era of assisted reproductive technology (2021)
- ESHRE Guideline: Endometriosis (2022)
- MedlinePlus Genetics: Inheritance risk assessment
- Indications and management of preimplantation genetic testing for monogenic conditions (2023)
- Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline (2017) | American Society for Reproductive Medicine | ASRM
- Male%20Infertility%20Unabridged%20Final.pdf
- Diagnosis of viable intrauterine pregnancy and of tubal ectopic pregnancy | Ectopic pregnancy and miscarriage: diagnosis and initial management | Guidance | NICE
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.